In A Pre-emptive Strike, Cipla Slashes Prices Of Key Anti-Cancer Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
The move to cut prices on anti-cancer drugs brings Cipla’s price on kidney cancer drug sorafenib lower than Natco’s price under the compulsory license awarded against Bayer.